Healthcare / Drug Manufacturers - Specialty & GenericBSE
$294.55
-4.70 (-1.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $147.3M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.9B
P/E
43.8x
↑EV/EBITDA
14.5x
↑ROE
3.0%
↑Gross Margin
48.2%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-1.8%
FCF CAGR
—
FCF margin
2.4%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.11B · net income $157.7M · FCF $147.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.11B | $6.11B | $5.43B | $4.73B | $6.46B |
| Net Income | $157.7M | $157.7M | $395.0M | $-837.9M | $430.2M |
| EBITDA | $787.1M | $787.1M | $1.02B | $438.3M | $1.22B |
| EPS | 4.98 | 4.98 | 13.12 | -30.36 | 15.59 |
| Gross Margin | 48.2% | 48.2% | 47.2% | 45.2% | 40.1% |
| Operating Margin | 12.6% | 12.6% | 10.0% | 10.3% | 14.6% |
| Net Margin | 2.6% | 2.6% | 7.3% | -17.7% | 6.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.48 | 1.20 | 1.13 |
| Current Ratio | 1.92 | 1.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $147.3M | $147.3M | $100.8M | $620.1M | $-1.16B |
| Returns | |||||
| ROE | 3.0% | 3.0% | 8.5% | -30.1% | 11.7% |
| Valuation | |||||
| P/E | 43.83 | 43.83 | 45.23 | — | 19.70 |
| EV/EBITDA | 14.54 | 14.54 | 19.71 | 28.00 | 10.21 |
| P/B | 1.75 | 1.75 | 3.83 | 3.22 | 2.31 |
| Growth & Yield | |||||
| Revenue Growth | 12.6% | 12.6% | 14.7% | -26.8% | — |
| EPS Growth | -62.0% | -62.0% | 143.2% | -294.7% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
73.8%
EPS terminal req.
$26.14
Spread vs growth
-135.8%
5Y implied EPS CAGR
44.7%
EPS terminal req.
$31.63
Spread vs growth
-106.8%
10Y implied EPS CAGR
26.2%
EPS terminal req.
$50.93
Spread vs growth
-88.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.6%
Start / end P/E
44.2x → 60.6x
EPS bridge
13.12 → 4.98
Residual
-23.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.